Nilotinib Biogaran

Nilotinib, the active ingredient in Nilotinib Biogaran, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It selectively blocks the BCR‑ABL, KIT and PDGFR kinases, reducing malignant cell proliferation, and is approved for Philadelphia chromosome‑positive chronic myeloid leukemia in the chronic phase.

GNH USA supplies Nilotinib Biogaran as a licensed, GDP‑compliant international pharmaceutical product, providing reliable access to oncology centres, hospitals and pharmacies worldwide. The company supports regulatory compliance, quality assurance and secure logistics for global procurement.

Nilotinib is a tyrosine kinase inhibitor used in the management of Philadelphia chromosome‑positive chronic myeloid leukemia. - Chronic myeloid leukemia – chronic phase: reduces disease progression and improves survival. - Chronic myeloid leukemia – accelerated phase: may achieve cytogenetic and molecular responses. - Chronic myeloid leukemia – blast phase: provides an additional therapeutic option when other TKIs are unsuitable.

Adverse reactions to nilotinib vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often transient. - Rash: skin erythema or pruritus. - Fatigue: generalized tiredness. - Myalgia: muscle aches. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Cardiovascular events: including arterial occlusive disease. - QT interval prolongation: risk of serious arrhythmias. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Pancreatitis: inflammation of the pancreas. - Severe neutropenia: marked reduction in white blood cells. - Severe skin reactions: such as Stevens‑Johnson syndrome.

Nilotinib requires careful monitoring to minimize risks. - Monitor blood counts: perform regular CBC to detect cytopenias. - Assess cardiac function: baseline ECG and periodic monitoring for QT prolongation. - Check liver enzymes: monitor hepatic function during therapy. - Avoid strong CYP3A4 inhibitors: concurrent use may increase nilotinib exposure. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Nilotinib can interact with several drug classes, affecting its safety and efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma concentrations. - QT‑prolonging agents (e.g., amiodarone, sotalol): increase risk of arrhythmia. - Antacids containing aluminum or magnesium: reduce nilotinib absorption.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower drug effectiveness. - Warfarin: may require more frequent INR monitoring. - St. John’s wort: can decrease nilotinib plasma levels.